Studiu: 4 din 10 cazuri de moarte subită la adulții tineri sunt legate de miocardita virală / Cum poate un virus să saboteze bătăile inimii și să oprească inima

https://archive.is/VA3wm (https://www.g4media.ro/studiu-4-din-10-cazuri-de-moarte-subita-la-adultii-tineri-sunt-legate-de-miocardita-virala-cum-poate-un-virus-sa-saboteze-bataile-inimii-si-sa-opreasca-inima.html)

Încă un articol despre moarte subită/miocardită în care dacă dai Ctrl-F “vaccin” găsești 0 rezultate. Evident nu este vorba de niciun virus, în timpul pandemiei cine murea de cancer sau mai stiu eu ce oficial murea de covid ca să se mai umfle statisticile, acum cine moare de “moarte subită” moare oficial de un virus fictiv.

E un lucru recunoscut că bărbații sub 40 de ani sunt predispuși la miocardită după vaccin, deși statisticile sunt muuult subestimate: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880674/

“Background

Myocarditis is a rare but significant adverse event associated with COVID‐19 vaccination, especially for men under 40. If the risk of myocarditis is not stratified by pertinent risk factors, it may be diluted for high‐risk and inflated for low‐risk groups. We sought to assess how the risk of myocarditis is reported in the literature.

Methods

In accordance with PRISMA standards, we reviewed primary publications in PubMed, Embase, Google Scholar and MedRxiv (through 3/2022) and included studies that estimated the incidence of myocarditis/pericarditis after receiving either the BNT162b2 (Pfizer), mRNA‐1273 (Moderna) or Ad26COVS1 (Janssen) vaccine. The main outcome was the percentage of studies using 4, 3, 2, 1 or 0 stratifiers (i.e. sex, age, dose number and manufacturer) when reporting the highest risk of myocarditis. Secondary outcomes included the incidence of myocarditis in males after dose 1 and 2 of the BNT162b2 (Pfizer) or mRNA‐1273 (Moderna) vaccine.

Results

The 29 included studies originated in North America, Europe, Asia, or were Worldwide. Of them, 28% (8/29) used all four stratifiers, and 45% (13/29) used 1 or 0 stratifiers. The highest incidence of myocarditis ranged from 8.1—39 cases per 100,000 persons (or doses) in studies using four stratifiers. Six studies reported an incidence greater than 15 cases per 100,000 persons (or doses) in males aged 12–24 after dose 2 of an mRNA‐based vaccine.

Conclusions

Only one in four articles reporting myocarditis used four stratifiers, and men younger than 40 receiving a second dose of an mRNA vaccine are at greatest risk.”

Ce e culmea: Pfizer si Moderna fac “vaccinuri” impotriva miocarditei/infarctului/accidentului vascular. Nu găsesc articolele momentant, dar ce e la fel de absurd e ca fac vaccinuri împotriva cancerului:

https://www.reuters.com/markets/deals/pfizer-gets-ok-43-bln-seagen-deal-after-donating-cancer-drug-rights-2023-12-12

Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
Dec 12 (Reuters) – Pfizer (PFE.N) said on Tuesday it expects to close its $43 billion deal to buy cancer drugmaker Seagen (SGEN.O) later this week and plans to create a new oncology division that includes the acquisition early next year.

https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-merck-begin-late-stage-study-mrna-cancer-therapy-2023-12-11

Moderna, Merck begin late-stage study for mRNA cancer therapy
Dec 11 (Reuters) – Moderna (MRNA.O) and Merck & Co (MRK.N) said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer.